press release: (OVA1) Vermillion Receives Notice of Allowance for Patent of Biomarker for Ovarian Cancer

Vermillion Receives Notice of Allowance for Patent of Biomarker for Ovarian Cancer


(press release) About OVA1
OVA1 is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using a unique multi-biomarker approach. In a published clinical trial, OVA1 achieved 99% sensitivity in detecting epithelial ovarian cancers (EOC). This included 96% sensitivity for stage I EOC, the earliest and most curable EOC stage, compared with 57% for the conventional biomarker CA125.(1) In addition, OVA1 found 70% of malignancies missed by non-specialist pre-surgical assessment,(1) and it increased detection of malignancy over ACOG guidelines from 77% to 94%.(2) As the first protein-based, In Vitro Diagnostic Multi-Variate Index Assay (IVDMIA) cleared by the FDA, OVA1 also represents a new class of software-based diagnostics.

Vermillion plans to reduce headcount, expenses - financial news (OVA1)

Vermillion Inc. VRML -2.76% plans to reduce its headcount and other expenses and focus on strengthening sales of its ovarian cancer testing product (OVA1)  this year.

financial news: Healthcare Stock on Watch; Vermillion (OVA1) climbs on Poster Presentation | Beacon Equity: Penny Stocks, Stock Alerts

Healthcare Stock on Watch; Vermillion climbs on Poster Presentation

Posted by g.zalesak on Mar 08, 2011

Vermillion Inc. (NASDAQ: VRML) shares are up nearly 2.5% to $4.99 mid-day on word of the company’s poster presentation of its preliminary results from its collaboration with John Hopkins University School of Medicine to identify biomarkers that improve the identification of malignant ovarian tumors.
The poster evaluated more than 20 candidate biomarkers for their ability to complement the company’s CA125 in distinguishing benign ovarian tumors from malignant ones.

(OVA1) Vermillion Attends 42nd Annual Meeting of the SGO March 7, 2011 /PRNewswire/ --

Note: see press release for more details "OVA1 improves the sensitivity of the ACOG referral guidelines for an ovarian mass" "OVA1 Has High Sensitivity in Identifying Ovarian Malignancy Compared to Preoperative Assessment and CA125"

(OVA1 ovarian cancer blood test) Vermillion Inks New Agreement with Quest Diagnostics - GLG News

Vermillion's OVA1 2010 Sales Target Is Looking Like a Moon Shot. How Will it Hit It? GenomeWeb (financial)

The test, approved last September, costs $650 and is reimbursed at $540 by Medicare, according to the company. (assuming U.S. dollars)

OVA1 - Vermillion Announces Relocation of Corporate Offices to Austin, Texas - MarketWatch

Vermillion Announces Relisting on NASDAQ - re: OVA1 ovarian diagnositic test (financial news)

For Vermillion, a Likely Off-Label Play for OVA1 as OVA2 Gains R&D Traction GenomeWeb

Note: financial news

(OVA1) Vermillion to Attend Society of Gynecologic Oncologists Meeting March 15-19 press release

Vermillion Emerges From Bankruptcy -- FREMONT, Calif., Jan. 22 /PRNewswire-FirstCall/ --

"This is a great day for all of our stakeholders as well as women who will benefit from OVA1,' said Gail Page, executive chair of Vermillion. 'We are in a position to resume development of our other programs in ovarian cancer and peripheral arterial disease,' she added."